This article is within the scope of WikiProject Viruses, a collaborative effort to improve the coverage of viruses on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.VirusesWikipedia:WikiProject VirusesTemplate:WikiProject Virusesvirus articles
Should be alright for uncontroversial information. They seemed to have sourced most of the info from this 2010 review. It would be better to cite that, although don't take the blogs word for it (drop me a line on my talk page if you can't access it). Also a quick NCBI search turned up this which is free and may also be useful. AIRcorn(talk)04:45, 26 November 2010 (UTC)[reply]
The section below seems entirely built by people going into clinicaltrials.gov and "reporting" on what is there.
This is not what we do in WP. Somebody can do this on their blog perhaps... The "lead" sentence is ridiculous in talking about the period from 2014-2018 and having a ref from 2016 (actually accepted in Nov 2015)
The more specific section below the table, is also done in the spirit of trying to provide "news" with language about some trial "ongoing" or "has started", all with no dates. One big WP:RELTIME ball of confusion. A bunch of raw spam "sources" as well. None of this is appropriate to the mission, as it is written.
Clinical research==
In 2014-2018 period a number of clinical trials were initiated for a wide range of oncolytic virus products, reflecting the ongoing clinical development of this class of therapy.[1]
Combined with dexamethasone plus a proteasomal inhibitor
NCT02101944
NCT02514382
Toca 511
Brain tumors
II/III
Not yet recruiting
Intratumoral
Combined with 5-FC and standard chemotherapy
NCT02414165
Solid tumors
I/II
Recruiting
Intratumoral Intravenous
Combined with 5-FC
NCT02576665
LOAd703
Pancreatic cancer
I/IIa
Recruiting
Intratumoral
Combined with standard of care treatment (gemcitabine plus nab-paclitaxel)
NCT02705196
Abbreviations: 5-FC, 5-fluorocytosine; GM-CSF, granulocyte macrophage colony-stimulating factor; IFNγ, interferon γ; MAGEA3, melanoma antigen family A3; s.c., sub cutem.*initiated between 2014, March 1 and 2015, October 31.
Talimogene laherparepvec was approved by the US FDA in 2015, with the brand name Imlygic, for the treatment of melanoma in patients with inoperable tumors.[2] In Jan 2016 it was approved in Europe for some inoperable melanoma.[3]
Oncorine, by Shanghai Sunway Biotech, was approved in China for Head and neck cancer in 2005.[4] It is based on the adenovirus H101.
RIGVIR, approved for melanoma treatment in Latvia (2004), then suspended 2019, Georgia (2015) and Armenia (2016) for melanoma treatment.
Article still lists Rigvir as approved somewhere, but its licence has been suspended in 2019 and in Latvian media there is talk of a criminal offence having been commited. Please see original ECHO-7 article for latest news: [5]KC LV (talk) 08:18, 12 July 2019 (UTC)[reply]
JX-594, by SillaJen, is currently in phase III for Hepatocellular Carcinoma.[6] Pexastimogene Devacirepvec(Pexa Vec) is a vaccinia virus based oncolytic immunotherapy designed to stimulate the immune system following infection and replication within tumor cells. JX-594 is a thymidine kinase-deleted Vaccinia virus plus GM-CSF.[7]
Reolysin, by Oncolytics Biotech, is in phase III for head and neck cancer.[8] An interim data release showed that this phase III had already obtained statistically significant tumor shrinkage in patients at their 6-week scan,[9] although the trial will not be complete until the overall survival data matures. Encouraging early results in colorectal cancer.[10][11] In total there are 31 clinical studies either completed or ongoing, including many testing Reolysin alongside standard chemotherapies in a variety of solid cancers.[12]
GL-ONC1, a modified vaccinia virus by Genelux Corporation, is in a Phase II study of intraperitoneal administration in patients with recurrent ovarian cancer.[15] It is also in a Phase Ib study, administered intravenously for solid tumours.[16] Additional trials are ongoing utilizing alternative methods of administration including intrapleural administration for patients with malignant pleural effusion,[17]intraperitoneal injection for patients with advanced peritoneal carcinomatosis,[18] and intravenous injection in combination therapy in head and neck cancers.[19][20]
ColoAd1 was developed by Psioxus Therapeutics Ltd using the process of directed evolution. ColoAd1 has successfully completed recruitment in a Phase I clinical trials of ColoAd1.[24] The trial involved recruiting patients with metastatic solid tumours where no standard treatment options were applicable. Samples from these patients showed evidence of virus replication within tumour sites after intravenous delivery. The second phase of the ColoAd1 study is planned to commence in 2014 and will examine efficacy in patients with metastatic colorectal cancer. Unlike many other oncolytic viruses, ColoAd1 can be administered by intravenous injection rather than requiring intra-tumoral injection. A second trial is comparing the efficacy of the intravenous approach versus direct intra-tumoural injection to assess the most effective method of delivering ColoAd1 to cancer patients (see the EU Clinical Trials Register for further details). A third trial is examining the intra-peritoneal route of delivery for women with late stage ovarian cancer.
Cavatak[25][26] is a coxsackie virus which is in phase II clinical trials for the treatment of malignant melanoma.[27]
ONCOS-102 is an engineered human serotype 5/3 adenovirus coding for human GM-CSF optimized to induce systemic anti-tumor T cell response in cancer patients. It has started a phase II trial for Unresectable Malignant Pleural Mesothelioma.[28] It has completed a phase I trial and is starting another for malignant pleural mesothelioma (MPM).[29]
SEPREHVIR (HSV-1716), by Virttu Biologics completed phase I in glioblastoma, in squamous cell carcinoma of head and neck, and in melanoma. Ongoing phase I dose escalation study of intratumoral HSV-1716 in pediatric/young adult patients with non–central nervous system solid tumours and a new phase I/IIa study in mesothelioma commenced in 2012.[30][31]
CGTG-102 (Ad5/3-D24-GMCSF), by Oncos Therapeutics,[32] while in phase I was already used to treat 200 advanced cancer patients in the company's Advanced Therapy Access Program.[33]
MV-NIS, an engineered measles virus has shown to be effective in targeted destruction of myeloma plasma cells. Radioactive Iodine imaging provides a novel technique for NIS gene expression monitoring.[34]
DNX-2401 is an oncolytic adenovirus with US Orphan drug status for glioma.[35]
^Clinical trial number NCT02562755 for "Hepatocellular Carcinoma Study Comparing Vaccinia Virus Based Immunotherapy Plus Sorafenib vs Sorafenib Alone (PHOCUS)" at ClinicalTrials.gov
^Clinical trial number NCT02562755 for "Hepatocellular Carcinoma Study Comparing Vaccinia Virus Based Immunotherapy Plus Sorafenib vs Sorafenib Alone (PHOCUS)" at ClinicalTrials.gov
^Clinical trial number NCT02630368 for "A Study of Metronomic CP and JX-594 in Patients With Advanced Breast Cancer and Advanced Soft-tissue Sarcoma (METROmaJX) (METROmaJX) (TRAVERSE)" at ClinicalTrials.gov
^Clinical trial number NCT02630368 for "A Study of Metronomic CP and JX-594 in Patients With Advanced Breast Cancer and Advanced Soft-tissue Sarcoma (METROmaJX) (METROmaJX)" at ClinicalTrials.gov
^Clinical trial number NCT02759588 for "GL-ONC1 Oncolytic Immunotherapy in Patients With Recurrent Ovarian Cancer" at ClinicalTrials.gov
^Clinical trial number NCT00794131 for "Safety Study of GL-ONC1, an Oncolytic Virus, in Patients With Advanced Solid Tumors" at ClinicalTrials.gov
^Clinical trial number NCT01766739 for "Intra-pleural Administration of GL-ONC1, a Genetically Modified Vaccinia Virus, in Patients With Malignant Pleural Effusion: Primary, Metastases and Mesothelioma" at ClinicalTrials.gov
^Clinical trial number NCT01443260 for "A Study of GL-ONC1, an Oncolytic Vaccinia Virus, in Patients With Advanced Peritoneal Carcinomatosis" at ClinicalTrials.gov
^Clinical trial number NCT01584284 for "Safety Study of Attenuated Vaccinia Virus (GL-ONC1)With Combination Therapy in Head & Neck Cancer" at ClinicalTrials.gov
^Mell LK, Brumund KT, Daniels GA, Advani SJ, Zakeri K, Wright ME, Onyeama SJ, Weisman RA, Sanghvi PR, Martin PJ, Szalay AA (October 2017). "Phase I Trial of Intravenous Oncolytic Vaccinia Virus (GL-ONC1) with Cisplatin and Radiotherapy in Patients with Locoregionally Advanced Head and Neck Carcinoma". Clinical Cancer Research. 23 (19): 5696–5702. doi:10.1158/1078-0432.CCR-16-3232. PMID28679776.
^Cite error: The named reference Rudin2014 was invoked but never defined (see the help page).
^Clinical trial number NCT01048892 for "Seneca Valley Virus-001 and Cyclophosphamide in Treating Young Patients With Relapsed or Refractory Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors With Neuroendocrine Features" at ClinicalTrials.gov, October 2012
^Clinical trial number NCT01017601 for "Seneca Valley Virus-001 After Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer" at ClinicalTrials.gov
^Clinical trial number NCT00832559 for "A Study of the Intratumoural Administration of CAVATAK to Head and Neck Cancer Patients" at ClinicalTrials.gov
^Clinical trial number NCT01227551 for "A Study of Intratumoral CAVATAK in Patients With Stage IIIc and Stage IV Malignant Melanoma" at ClinicalTrials.gov
^Clinical trial number NCT02879669 for "A Randomised Phase II Open-label Study With a Phase Ib Safety lead-in Cohort of ONCOS-102, an Immune-priming GM-CSF Coding Oncolytic Adenovirus, and Pemetrexed/Cisplatin in Patients With Unresectable Malignant Pleural Mesothelioma " at ClinicalTrials.gov